Patient Square Capital
DFTX icon

Patient Square Capital’s Definium Therapeutics DFTX Stock Holding History

Patient Square Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$14.7M Buy
+385,000
New +$16.2M 2.34% 10
2026
Q2 		– Sell
-331,000
Closed -$6.26M – 31
2026
Q1 		$6.26M Buy
+331,000
New +$5.62M 1.11% 23

Other funds holding DFTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Patient Square Capital's DFTX Position: Q3 2026 in Review

Patient Square Capital opened a new position in Definium Therapeutics (DFTX) in Q3 2026: 385,000 shares worth $14.7M. The stake represents 2.34% of the portfolio and ranks #10 among its holdings. This is a return to the name: Patient Square Capital previously reported a position in DFTX as recently as Q1 2026.

Patient Square Capital first reported a position in DFTX in Q1 2026 and has held it in 2 quarters since. 159 funds tracked by Wall St. Rank hold DFTX as of Q3 2026.

  • Patient Square Capital held 385,000 shares of Definium Therapeutics worth $14.7M as of Q3 2026.
  • Definium Therapeutics was a new Patient Square Capital position in Q3 2026.
  • Definium Therapeutics made up 2.34% of Patient Square Capital's portfolio in Q3 2026, its #10 holding.
  • Patient Square Capital first reported a position in Definium Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2026.

Based on Patient Square Capital's 13F filing for Q3 2026, filed 10 Nov 2026.